Humoral Immune Response Clinical Trial
Official title:
Effect of Paraprobiotic Lactobacillus Plantarum IS-10506 on Humoral Immune Response of Indonesian Elementary School Children: a Double Blind, Randomized, Placebo-controlled Trial
| Verified date | April 2019 |
| Source | Gadjah Mada University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study is aimed to determine effect of paraprobiotic Lactobacillus plantarum IS-10506 on humoral immune response by measuring faecal sIgA and blood IgG, IgM, and IgA
| Status | Completed |
| Enrollment | 79 |
| Est. completion date | April 4, 2019 |
| Est. primary completion date | January 4, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 7 Years to 9 Years |
| Eligibility |
Inclusion Criteria: - children at age of 7-9 years - have normal body mass index (BMI) i.e. -2 = z-score < +1, slightly overweight z-score < +1.5, and slightly underweight z-score > -3. Exclusion Criteria: - allergic to milk - consuming other probiotic product - he/she do not want to stop consumption & doing washout for 2 weeks. |
| Country | Name | City | State |
|---|---|---|---|
| Indonesia | Universitas Gadjah Mada | Sleman | D.I.Yogyakarta |
| Lead Sponsor | Collaborator |
|---|---|
| Gadjah Mada University |
Indonesia,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Serum IgG | Measuring IgG (ng/mL) in collected serum | 90 days | |
| Primary | Serum IgA | Measuring IgA (ng/mL) in collected serum | 90 days | |
| Primary | Serum IgM | Measuring IgM (ng/mL) in collected serum | 90 days | |
| Primary | Faecal sIgA | Measuring sIgA (ng/mL) in collected feses | 90 days | |
| Secondary | Weight | Measuring weight (kg) change | 90 days | |
| Secondary | Height | Measuring height (cm) change | 90 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03164967 -
Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16
|
Phase 4 |